Related Experiment Video
Updated: May 9, 2026

Cerebrospinal Fluid MicroRNA Profiling Using Quantitative Real Time PCR
Published on: January 22, 2014
MicroRNA profiling in the serums of SCA3/MJD patients
Yuting Shi1, Fengzhen Huang, Beisha Tang
11Department of Neurology, Xiangya Hospital, Central South University , Changsha, Hunan , China.
Abstract:
Spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD) is the most common type of spinocerebellar ataxia in China. However, the pathogenesis of SCA3/MJD is still unknown. MicroRNAs (miRNAs) have been repeatedly demonstrated to exist in human peripheral serum in a bio-stable form and have been shown to be useful biomarkers for other neurodegenerative disorders. However, no study of SCA3/MJD patients has assessed specific changes in regulatory miRNAs. Therefore, we systematically used the miRCURYTM LNA Array, followed by quantitative real-time polymerase chain reaction validation, to access miRNA expression levels in the serums from SCA3/MJD patients. Our results show that miR-25, miR-125b, miR-29a, and miR-34b could be potential biomarkers for SCA3/MJD and could be used to further investigate the pathogenesis of SCA3/MJD and drug development.
Insights
Spinocerebellar ataxia type 3 (SCA3/MJD) biomarkers were identified in patient serum. Researchers found specific microRNAs (miRNAs) could aid in understanding SCA3/MJD pathogenesis and developing new treatments.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- Spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD) is a prevalent neurodegenerative disorder in China with unknown pathogenesis.
- MicroRNAs (miRNAs) are stable molecules in peripheral serum, showing potential as biomarkers for neurodegenerative diseases.
- Previous studies have not investigated specific miRNA alterations in SCA3/MJD patients.
Purpose of the Study:
- To identify specific serum microRNA (miRNA) expression changes in patients with Spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD).
- To explore the potential of these miRNAs as biomarkers for SCA3/MJD diagnosis and pathogenesis research.
- To lay the groundwork for future drug development targeting SCA3/MJD.
Main Methods:
- Systematic analysis of serum miRNA expression using the miRCURYTM LNA Array.
- Validation of identified miRNA expression levels through quantitative real-time polymerase chain reaction (qRT-PCR).
- Comparison of miRNA profiles between SCA3/MJD patients and control groups (implied).
Main Results:
- Identified specific serum microRNAs (miRNAs) that are differentially expressed in SCA3/MJD patients.
- Found miR-25, miR-125b, miR-29a, and miR-34b to be significantly altered in SCA3/MJD serum.
- These miRNAs show potential as diagnostic or prognostic biomarkers for SCA3/MJD.
Conclusions:
- The identified miRNAs (miR-25, miR-125b, miR-29a, miR-34b) represent potential biomarkers for Spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD).
- These miRNAs may offer insights into the underlying pathogenesis of SCA3/MJD.
- Further investigation of these miRNAs could facilitate the development of novel therapeutic strategies and drug discovery for SCA3/MJD.
Related Concept Videos
MicroRNAs
MicroRNAs
MicroRNAs

